Clinical trials: Adult Atopic Dermatitis
Atopic Dermatitis
Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis
This is a Randomized, Double-blind, Vehicle-Controlled, Seamless and Adaptive-designed Phase II/III Study to Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Adult Patients with Mild-to-Moderate Atopic Dermatitis.
- Trial name
- MARBLE-23 (NCT04717310)
- Testing
- SHR0302 Ointment, Vehicle
- Where
- 31 sites in China
- Volunteers
- 645 people
- Sponsor
- Reistone Biopharma Company Limited
Atopic Dermatitis, Atopic Dermatitis Eczema
Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%
The investigational lotion is envisaged as an short- and long term "Ease \& Prevent" monotherapy for adults and children with mild to moderate eczema.
- Conditions
- Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Rash, Rash
- Trial name
- ATOFEX-1 (NCT05461456)
- Testing
- Fexofenadine Hydrochloride Topical Lotion 1% (OP2101)
- Where
- Bangladesh
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- OrchestratePharma GmbH
Dermatitis, Atopic
A Study of JNJ-39758979 in Adult Japanese Patients With Moderate Atopic Dermatitis
The purpose of this study is to evaluate the safety, tolerability, and efficacy of JNJ-39758979 in adult Japanese patients with moderate, active atopic dermatitis.
- Trial name
- NCT01497119
- Testing
- JNJ-39758979, 300 mg, JNJ-39758979, 100 mg
- Where
- 13 sites in Japan
- Volunteers
- 88 people
- Sponsor
- Janssen Pharmaceutical K.K.
Chronic Hand Eczema (CHE)
Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity (Investigator's Global Assessement…
- Trial name
- TRuE-CHE2 (NCT05233410)
- Testing
- Ruxolitinib cream, Vehicle
- Where
- 39 sites in United States, Bulgaria and 5 more
- Sponsor
- Incyte Corporation
Mild to Moderate Atopic Dermatitis
Phase 2 Study of HL-009 Liposomal Gel to Treat Mild to Moderate Atopic Dermatitis
The objective of this phase 2 study is to evaluate the safety and efficacy of HL-009 Liposomal Gel in adult patients with mild to moderate atopic dermatitis (AD).
- Trial name
- NCT01568489
- Testing
- HL-009 Liposomal Gel
- Where
- 7 sites in United States
- Volunteers
- 120 people
- Sponsor
- HanAll BioPharma Co., Ltd.
Atopic Dermatitis
A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)
The reason for this study is to assess the impact of lebrikizumab on vaccine immune response in adult participants with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT04626297
- Testing
- Lebrikizumab
- Where
- 85 sites in United States
- Volunteers
- 254 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis
The purpose of the study is to evaluate the effect of ruxolitinib cream on itch in participants with Atopic Dermatitis.
- Trial name
- SCRATCH-AD (NCT04839380)
- Testing
- ruxolitinib cream
- Where
- 2 sites in Canada
- Volunteers
- 49 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
The purpose of the study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD).
- Trial name
- PossibILity (NCT07277660)
- Testing
- Galvokimig
- Where
- 59 sites in United States, Bulgaria and 7 more
- Volunteers
- 165 people
- Sponsor
- UCB Biopharma SRL
Atopic Dermatitis
Validation of the Short-term Antimicrobial Action of Transplanted Bacteria
Unlike healthy control skin, the skin of patients with atopic dermatitis (AD) is frequently colonized by Staphylococcus aureus (S. aureus), putting these patients at increased risk of S. aureus skin infections.
- Trial name
- NCT01959113
- Testing
- Autologous Microbiome Transplant
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of California, San Diego
Atopic Dermatitis
A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)
The co-primary objectives of the study are to: Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD).
- Trial name
- ROCKET-Horizon (NCT05651711)
- Testing
- Rocatinlimab
- Where
- 197 sites in United States, Australia and 19 more
- Volunteers
- 726 people
- Sponsor
- Amgen
Atopic Dermatitis
A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis
A Phase 1B, multi-center, double-blind, placebo-controlled, randomized, multiple ascending dose (MAD) clinical study is designed to evaluate ASLAN004 versus placebo in patients who have moderate-severe AD.
- Trial name
- NCT04090229
- Testing
- ASLAN004
- Where
- 11 sites in United States, Australia and 1 more
- Volunteers
- 52 people
- Sponsor
- ASLAN Pharmaceuticals
Atopic Dermatitis
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy, pharmacokinetics, and Safety of repeat subcutaneous doses of FB825 in adults with moderate-to-severe atopic dermatitis.
- Trial name
- NCT06397911
- Testing
- FB825
- Where
- 16 sites in United States, Taiwan
- Volunteers
- 114 people
- Sponsor
- Oneness Biotech Co., Ltd.
Atopic Dermatitis
A Study of Orally Administered IPG7236 in Healthy Adult Participants
The study is a phase 1, randomized, double-blind, placebo-controlled, single and multiple dose escalation study to evaluate the safety, tolerability, pharmacokinetic and food effect of orally administered IPG7236 in healthy adult…
- Trial name
- NCT05288543
- Testing
- IPG7236- Single ascending dose, IPG7236- Multiple ascending dose
- Where
- Australia
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Nanjing Immunophage Biotech Co., Ltd
Atopic Dermatitis
A Study to Evaluate the Efficacy and Safety of SIM0718 in Adult and Adolescent Patients With Moderate to Severe Atopic Dermatitis
This study will evaluate the efficacy and safety of SIM0718 in adolescents (12- < 18 years) and adults (18-75 years) with moderate to severe AD.
- Trial name
- NCT06477835
- Testing
- SIM0718 Injection
- Where
- China
- Volunteers
- 259 people
- Sponsor
- Simcere Pharmaceutical Co., Ltd
Atopic Dermatitis
A Study of Two Different Formulations of 611 in Healthy Adult Subjects in China
The main purpose of this study is to compare two different formulations (mixtures) of 611 in healthy participants. This study will compare how much of each formulation gets into the blood stream.
- Trial name
- 611 (NCT07042113)
- Testing
- new formulations of 611, existing formulations of 611
- Where
- 2 sites in China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Atopic Dermatitis
Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults
This is a double-blind, randomized, vehicle controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% compared to vehicle control cream in pediatric and adult subjects with atopic dermatitis.
- Trial name
- NCT05014568
- Testing
- tapinarof cream, 1%, Vehicle cream
- Where
- 67 sites in United States, Canada
- Volunteers
- 407 people
- Sponsor
- Organon and Co
Atopic Dermatitis
An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in China
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Upadacitinib is an approved drug for treating AD.
- Trial name
- REACH-AD (NCT06421740)
- Where
- 38 sites in China
- Volunteers
- 1,000 people
- Sponsor
- AbbVie
Atopic Dermatitis
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic…
- Trial name
- Level Up (NCT05601882)
- Testing
- Dupilumab, Upadacitinib
- Where
- 257 sites in United States, Australia and 27 more
- Volunteers
- 920 people
- Sponsor
- AbbVie
Atopic Dermatitis, Skin Diseases
Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS)
This study investigates 3 different doses of orismilast modified release compared to placebo in adult patients with moderate-to-severe atopic dermatitis.
- Trial name
- NCT05469464
- Testing
- Orismilast modified release tablets
- Where
- 48 sites in United States, Germany and 2 more
- Volunteers
- 235 people
- Sponsor
- UNION therapeutics
Atopic Dermatitis
To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adults With Moderate-to-severe Atopic Dermatitis
The purpose of this study is to determine the effect of GBR 830 on biomarkers in atopic dermatitis to enable further studies in this indication.
- Trial name
- NCT02683928
- Testing
- GBR 830
- Where
- 17 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- Ichnos Sciences SA